New antibody (TRIM21) linked to blood-brain barrier leaks

Credibility

Interest

Share:2 min read

Key Takeaway

Researchers found that some people with neuromyelitis optica spectrum disorder (NMOSD) have antibodies against a protein called TRIM21 that can make the brain’s protective blood-brain barrier leakier.

What They Found

The team looked for antibodies that damage the blood-brain barrier (BBB) in NMOSD patients who did not have a previously known antibody. They identified antibodies against TRIM21 in about 27% of NMOSD patients and showed these antibodies attach to cells that line brain blood vessels. When these TRIM21 antibodies hit those cells in lab models, they turned on a cell signal called NF-κB (a kind of alarm system) and lowered levels of claudin-5 (a protein that helps seal the barrier), which made the barrier leakier. Removing the TRIM21 antibodies from patient samples reduced the barrier-damaging effect, suggesting these antibodies play a direct role. The antibody effects were seen in several lab models of the BBB, which gives more confidence the finding is real and not just a single test result.

Who Should Care and Why

People with NMOSD and their caregivers should care because a leaky BBB can make attacks or symptoms worse by letting harmful immune substances into the brain and spinal cord — imagine a house with a damaged roof letting rain in. Doctors and care teams may use this information to better understand why some patients get more severe attacks and to consider different testing or treatment plans. Researchers can use this finding to look for treatments that block TRIM21 antibodies or their effects, similar to fixing a hole in the roof instead of only mopping the floor after leaks. Patients who test positive for TRIM21 antibodies might benefit from closer monitoring or therapies that protect the BBB, but this needs more clinical study. Caregivers may find it helpful to know that new causes of BBB damage are being found, which could lead to better personalized care in the future.

Important Considerations

This study used lab models, not direct tests in people, so results may not fully match what happens inside a living person. Not all NMOSD patients have TRIM21 antibodies, so this explains only a subgroup of patients. More clinical studies are needed before doctors change treatments based on TRIM21 testing.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Early Research MS Genetics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Acta neuropathologica communications often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News